doxorubicin

Doxorubicin (Adriamycin) is a fluorescent anthracycline antitumor antibiotic that inhibits Topoisomerase I/II, induces apoptosis and autophagy, downregulates the AMPK signaling pathway, and is commonly used in cancer chemotherapy as well as in models of nephritis and heart failure.

Doxorubicin-SMCC is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[1].

N-(Iodoacetamido)-Doxorubicin is an ADC linker employed in the synthesis of antibody-drug conjugates (ADCs)[1].

Zoptarelin doxorubicin, also known as AEZS-108, is an LHRH agonist. Zoptarelin doxorubicin is a peptide agonist of the gonadotropin releasing hormone-1 receptor (GnRH-1R) that is conjugated to the anthracycline antibiotic doxorubicin with potential antineoplastic activity. Zoptarelin doxorubicin binds to GnRH-1Rs, which may be highly expressed on endometrial and ovarian tumor cell membrane surfaces, and is internalized. Once inside the cell, the doxorubicin moiety of this agent intercalates into DNA and inhibits the topoisomerase II activity, which may result in the inhibition of tumor cell DNA replication and tumor cell proliferation

Doxorubicin hydrochloride is an anthracycline antibiotic with cytotoxic and antitumor activity. It is an effective inhibitor of human DNA topoisomerase I and II, with IC50 values of 0.8 μM and 2.67 μM, respectively. In addition to inhibiting DNA topoisomerases, it can reduce the phosphorylation of AMPK and its downstream target, acetyl-CoA carboxylase. Doxorubicin hydrochloride also induces apoptosis and autophagy. In animal studies, it is commonly used to induce models of acute renal failure, chronic kidney injury, and heart failure.

Adriamycin Aglycone, also known as Doxorubicinone, is an oncolytic agent. It is a metabolite of Doxorubicin which binds to the DNA minor-groove.

Doxorubicin-MVCP (MC-Val-Cit-PAB-Doxorubicin) is a Doxorubicin derivative with an MC-Val-Cit-PAB linker.

Pantoprazole Sodium Hydrate (BY1023 (sodium hydrate)) is a proton pump inhibitor drug, used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.

Pantoprazole (BY1023) is a proton pump inhibitor used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease.

Pantoprazole sodium (Pantecta) is the sodium salt form of a substituted benzimidazole with proton pump inhibitor activity. Pantoprazole sodium is a lipophilic, weak base that crosses the parietal cell membrane and enters the acidic parietal cell canaliculus where it becomes protonated, producing the active metabolite sulfenamide, which forms an irreversible covalent bond with two sites of the H+/K+-ATPase enzyme located on the gastric parietal cell, thereby inhibiting both basal and stimulated gastric acid production.

NSC348884 is a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis, inhibits cell proliferation at an IC50 of 1.7-4.0 μM in distinct cancer cell lines.

Mc-doxhzn is a protein-binding prodrug of DOXUbicin (DNA topoisomerase II inhibitor) with acid sensitivity.

Nemorubicin (PNU 152243) is a doxorubicin derivative that differs significantly from its parent drug in terms of spectrum of antitumor activity, metabolism and toxicity profile. The drug is active on tumors resistant to alkylating agents, topoisomerase II inhibitors and platinum derivatives.

MC-DOXHZN hydrochloride is an albumin-binding prodrug of Doxorubicin. Doxorubicin is a DNA topoisomerase II inhibitor.

MA-PEG4-VC-PAB-DMEA-Doxorubicin is a thiol-reactive Drug-linker. Doxorubicin is a cytotoxic anthracycline broad-spectrum antibiotic, commonly used as a tumor chemotherapy agent. MA-PEG4-VC-PAB-DMEA-Doxorubicin can be used in the synthesis of antibody-drug conjugates (ADC).

N3-PEG4-YPYDVPDYA-Doxorubicin forms part of an antibody-drug conjugate, consisting of the anthracycline antibiotic Doxorubicin and a degradable ADC linker, N3-PEG4-YPYDVPDYA.

N3-PEG4-DYKDDDD-Doxorubicin is a component of an antibody-drug conjugate, comprising the anthracycline antibiotic doxorubicin and the degradable ADC linker N3-PEG4-DYKDDDD.

Biotin-doxorubicin is a biotin-labeled form of doxorubicin. Doxorubicin is a broad-spectrum anthracycline antibiotic and serves as a topoisomerase II (topoisomerase II) inhibitor.

Azide-PEG4-VC-PAB-Doxorubicin is an agent-linker conjugate used in antibody-drug conjugate (ADC) applications, comprising the cytotoxic anthracycline antibiotic Doxorubicin linked through the Azide-PEG4-VC-PAB linker [1].

Cholesterol-doxorubicin is a cholesterol conjugate characterized by excellent storage stability, reduced blood toxicity, and controlled drug delivery properties. Cholesterol-doxorubicin is applicable in studies focused on drug delivery.

Doxorubicin hydrochloride (Standard) is a reference standard for research and analysis in studies involving Doxorubicin hydrochloride. Doxorubicin hydrochloride is an anthracycline antibiotic with cytotoxic and antitumor activity. It is an effective inhibitor of human DNA topoisomerase I and II, with IC50 values of 0.8 μM and 2.67 μM, respectively. In addition to inhibiting DNA topoisomerases, it can reduce the phosphorylation of AMPK and its downstream target, acetyl-CoA carboxylase. Doxorubicin hydrochloride also induces apoptosis and autophagy. In animal studies, it is commonly used to induce models of acute renal failure, chronic kidney injury, and heart failure.

Aldoxorubicin hydrochloride is an albumin-binding prodrug of Doxorubicin, a DNA topoisomerase II inhibitor. Aldoxorubicin hydrochloride is released from albumin under acidic conditions. Aldoxorubicin hydrochloride exhibits potent antitumor activities in various cancer cell lines and in murine tumor models.

Aldoxorubicin has effective antitumor activities in various cancer cell lines and in murine tumor models. Aldoxorubicin is an albumin-binding prodrug of Doxorubicin (DNA topoisomerase II inhibitors).

Faridoxorubicin (AVA-6000) is a prodrug that targets fibroblast activation protein alpha (FAPα). It releases active doxorubicin through FAPα-mediated cleavage, enhancing drug exposure within tumors while reducing cardiac toxicity. Faridoxorubicin holds potential for research in solid tumors, such as liver metastases from colorectal cancer.